APA (7th ed.) Citation

Schwarzbich, M., Schöning, T., Cremer, M., Kriegsmann, K., Ho, A. D., & Witzens-Harig, M. (2016). Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment. Leukemia and lymphoma, 57(7), . https://doi.org/10.3109/10428194.2015.1113274

Chicago Style (17th ed.) Citation

Schwarzbich, Mark-Alexander, Tilman Schöning, Martin Cremer, Katharina Kriegsmann, Anthony Dick Ho, and Mathias Witzens-Harig. "Efficacy and Toxicity of a Rituximab and Methotrexate Based Regimen (GMALL B-ALL/NHL 2002 Protocol) in High Risk Diffuse Large Cell B-cell Lymphoma Patients as a First Line Treatment." Leukemia and Lymphoma 57, no. 7 (2016). https://doi.org/10.3109/10428194.2015.1113274.

MLA (9th ed.) Citation

Schwarzbich, Mark-Alexander, et al. "Efficacy and Toxicity of a Rituximab and Methotrexate Based Regimen (GMALL B-ALL/NHL 2002 Protocol) in High Risk Diffuse Large Cell B-cell Lymphoma Patients as a First Line Treatment." Leukemia and Lymphoma, vol. 57, no. 7, 2016, https://doi.org/10.3109/10428194.2015.1113274.